Joaquim Bellmunt

Also affiliated with Dana-Farber Cancer Institute, Hospital Del Mar, Municipal Institute for Medical Research

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 12 papers. Top paper: “Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial”.

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology(2021)10.1016/s1470-2045(21)00004-8

N/A

5.8DataRank · unranked

418 citations

Maha Hussain, Jürgen E. Gschwend, Peter Albers, Stéphane Oudard, Daniel Castellano +21 more

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

Journal of Clinical Oncology(2020)10.1200/jco.19.01213

N/A

4.9DataRank · unranked

294 citations

Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Petros Grivas, Joaquim Bellmunt +11 more

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

Annals of Oncology(2022)10.1016/j.annonc.2022.11.012

N/A

3.4DataRank · unranked

116 citations

Daniel Castellano, Petros Grivas, David J. Vaughn, Thomas Powles, Jacqueline Vuky +15 more

Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer

Nature Communications(2021)10.1038/s41467-021-26042-z

N/A

2.9DataRank · unranked

163 citations

Yingtian Xie, Alba Font‐Tello, Klothilda Lim, Sudeepa Syamala, Xintao Qiu +33 more

Enzalutamide for the Treatment of Prostate Cancer: Results and Implications of the AFFIRM Trial

Future Oncology(2014)10.2217/fon.13.275

N/A

0.776DataRank · unranked

12 citations

Mary-Ellen Taplin, Joaquim Bellmunt, Rosa Nadal

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3089

N/A

0.587DataRank · unranked

49 citations

Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae‐Lyun Lee +26 more

RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics

Journal of Clinical Investigation(2021)10.1172/jci147849

N/A

0.533DataRank · unranked

34 citations

Amruta S. Samant, Amin H. Nassar, Jonathan So, Elizabeth P. Garcia, Catherine R. Curran +13 more

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

ESMO Open(2024)10.1016/j.esmoop.2024.103972

N/A

0.515DataRank · unranked

30 citations

M.D. Galsky, Thomas Powles, Daniel P. Petrylak, Joaquim Bellmunt, Y. Loriot +19 more

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer

(2020)10.1101/2020.09.13.291328

N/A

0.464DataRank · unranked

21 citations

Yingtian Xie, Alba Font‐Tello, Klothilda Lim, Sudeepa Syamala, Xintao Qiu +30 more

Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study

British Journal of Cancer(2023)10.1038/s41416-022-01991-4

N/A

0.406DataRank · unranked

14 citations

Pablo Maroto, Albert Font, Cristina Martin, Begoña Mellado, Alex Corbera +14 more

Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study

Clinical Genitourinary Cancer(2024)10.1016/j.clgc.2024.102123

N/A

0.385DataRank · unranked

12 citations

Pablo Maroto, Teresa Bonfill, Federico Vazquez, Jose Luis Perez-Gracia, Nuria Juanpere +6 more

Patterns of chemotherapy administration in bladder preservation therapy (BPT) for muscle-invasive bladder cancer (MIBC).

Carolina Digital Repository (University of North Carolina at Chapel Hill)(2024)10.17615/7y09-8d51

N/A

0DataRank · unranked

0 citations

Evan Y. Yu, Lauren C. Harshman, Nielsen, Matthew Edward, Yu‐Ning Wong, Andrew Z. Wang +14 more